3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
2
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumors
1
Interventions
Injections
27
Carboplatin
18
Docetaxel
14
pembrolizumab
13
Paclitaxel
12
Bevacizumab
10
durvalumab
8
Nivolumab
8
Cisplatin
8
Fluorouracil
7
Pemetrexed
6
Oxaliplatin
6
Leucovorin
6
trifluridine tipiracil drug combination
5
toripalimab
5
tislelizumab
5
linifanib
5
Capecitabine
5
zimberelimab
4
talazoparib
4
olaparib
4
fludarabine
4
Panobinostat
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Everolimus
4
tremelimumab
3
sotorasib
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Solid Tumors
×
Maximum Tolerated Dose
×
Clear all
NCT02994953
2024-09-20
COMBO
EMD Serono
Phase 1
Terminated
52 enrolled
34 charts